A phase II study of carboplatin plus gemcitabine in advanced non-small- cell lung cancer (NSCLC): A hoosier oncology group study

Elizabeth W. Ng, Alan B. Sandler, Leslie Robinson, Lawrence H. Einhorn

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

The purpose of this study was to evaluate the toxicity and determine the response rate, duration of remission, and survival using gemcitabine plus carboplatin in non-small cell lung cancer (NSCLC). This was a phase II study of gemcitabine and carboplatin in chemotherapy-naive patients with advanced NSCLC and Karnofsky Performance Status of at least 80. Gemcitabine was administered intravenously at 1,000 mg/m2 weekly for 3 weeks followed by 1 week rest. Carboplatin was administered immediately after gemcitabine at an area under the curve (AUC) of 5 given intravenously on day 1 of an every-4- week cycle. Seven patients were entered in the study and five were evaluable for toxicity. The median age of patients was 68 years (range, 52-72). The protocol was prematurely terminated because of severe and unexpected hematologic toxicity. Grade 3-4 thrombocytopenia was observed in four of the first five patients. These toxicities were all observed with the first course of chemotherapy. There were no objective responses seen. Median survival time was 130 days. Carboplatin plus gemcitabine was a logical combination. However, because of the severe thrombocytopenia associated with this regimen, we do not recommend this two-drug combination in the dose and schedule used in this study.

Original languageEnglish (US)
Pages (from-to)550-553
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number6
DOIs
StatePublished - Dec 1 1999

Keywords

  • Carboplatin
  • Gemcitabine
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of carboplatin plus gemcitabine in advanced non-small- cell lung cancer (NSCLC): A hoosier oncology group study'. Together they form a unique fingerprint.

  • Cite this